<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="92595">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02135354</url>
  </required_header>
  <id_info>
    <org_study_id>s55829</org_study_id>
    <secondary_id>2013-004420-11</secondary_id>
    <secondary_id>IWT-TBM 130233</secondary_id>
    <nct_id>NCT02135354</nct_id>
  </id_info>
  <brief_title>Belgian Trial With Azithromycin During Acute COPD Exacerbations</brief_title>
  <acronym>BACE</acronym>
  <official_title>Azithromycin for Acute COPD Exacerbations With Hospitalization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wim Janssens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Agentschap voor Innovatie door Wetenschap en Technologie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Katholieke Universiteit Leuven</source>
  <oversight_info>
    <authority>Belgium: Federal Agency for Medicines and Health Products, FAMHP</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project (funded by the IWT-TBM program) will organize a randomised placebo-controlled
      multicenter intervention trial in 500 COPD patients to study the effectiveness and safety of
      azithromycin therapy in the acute setting of COPD exacerbations requiring hospital
      admission.  Although long-term use of azithromycin is proven effective to prevent
      exacerbations, inherent risks outweigh the benefits. By reducing the dose and duration of
      the azithromycin treatment and by restricting the treatment to acute periods with highest
      risk for treatment failure, benefits may counterbalance potential side effects, which may
      result in a new treatment strategy for these acute events.

      The present study is designed by the services of respiratory medicine of the Leuven and
      Ghent University hospitals but will run in total in 17 different large hospitals in Belgium,
      of which 12 are located in Flanders.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Time to treatment failure</measure>
    <time_frame>Will be assessed between day 1 (from 1 hour after first drug intake) till day 90 (24 hours after last study drug intake)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Clinical failure is a composite endpoint as multiple clinical interventions may indicate that an initiated therapy is failing. Clinical failure is defined as either death or the referral to intensive care for respiratory reasons, the requirement of additional systemic steroids or new antibiotics for respiratory reasons, or the diagnosis of a new exacerbation after discharge.
Primary outcome measure will also be analysed in following subgroups:
Male vs female
Smoker vs ex-smoker (stopped smoking &gt; 6 months)
GOLD A, B vs GOLD C vs GOLD D
former GOLD  I, II vs III vs IV
High CRP (&gt; 50 mg/dL) vs low CRP (&lt; 50 mg/dL)
Age &lt; 60 years vs age 60 - 70 years vs age &gt; 70 years
Anthonissen I vs Anthonissen II vs Anthonissen III at admission
ICS use vs no ICS use</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of treatment failures</measure>
    <time_frame>Will be assessed on day 90 (last day of treatment phase) and day 270 (last day of follow-up phase)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Secondary outcome measure will also be analysed in following subgroups:
Male vs female
Smoker vs ex-smoker (stopped smoking &gt; 6 months)
GOLD A, B vs GOLD C vs GOLD D
former GOLD  I, II vs III vs IV
High CRP (&gt; 50 mg/dL) vs low CRP (&lt; 50 mg/dL)
Age &lt; 60 years vs age 60 - 70 years vs age &gt; 70 years
Anthonissen I vs Anthonissen II vs Anthonissen III
ICS use vs no ICS use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to new exacerbation</measure>
    <time_frame>Will be assessed on day 90 (last day of treatment phase) and day 270 (last day of follow-up phase)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Secondary outcome measure will also be analysed in following subgroups:
Male vs female
Smoker vs ex-smoker (stopped smoking &gt; 6 months)
GOLD A, B vs GOLD C vs GOLD D
former GOLD  I, II vs III vs IV
High CRP (&gt; 50 mg/dL) vs low CRP (&lt; 50 mg/dL)
Age &lt; 60 years vs age 60 - 70 years vs age &gt; 70 years
Anthonissen I vs Anthonissen II vs Anthonissen III at admission
ICS use vs no ICS use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of new exacerbations</measure>
    <time_frame>Will be assessed on day 90 (last day of treatment phase) and day 270 (last day of follow-up phase)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Secondary outcome measure will also be analysed in following subgroups:
Male vs female
Smoker vs ex-smoker (stopped smoking &gt; 6 months)
GOLD A, B vs GOLD C vs GOLD D
former GOLD  I, II vs III vs IV
High CRP (&gt; 50 mg/dL) vs low CRP (&lt; 50 mg/dL)
Age &lt; 60 years vs age 60 - 70 years vs age &gt; 70 years
Anthonissen I vs Anthonissen II vs Anthonissen III at admission
ICS use vs no ICS use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of exacerbations</measure>
    <time_frame>Will be assessed on day 90 (last day of treatment phase) and day 270 (last day of follow-up phase)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Secondary outcome measure will also be analysed in following subgroups:
Male vs female
Smoker vs ex-smoker (stopped smoking &gt; 6 months)
GOLD A, B vs GOLD C vs GOLD D
former GOLD  I, II vs III vs IV
High CRP (&gt; 50 mg/dL) vs low CRP (&lt; 50 mg/dL)
Age &lt; 60 years vs age 60 - 70 years vs age &gt; 70 years
Anthonissen I vs Anthonissen II vs Anthonissen III at admission
ICS use vs no ICS use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days of hospitalisation</measure>
    <time_frame>Will be assessed on day 90 (last day of treatment phase) and day 270 (last day of follow-up phase)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Secondary outcome measure will also be analysed in following subgroups:
Male vs female
Smoker vs ex-smoker (stopped smoking &gt; 6 months)
GOLD A, B vs GOLD C vs GOLD D
former GOLD  I, II vs III vs IV
High CRP (&gt; 50 mg/dL) vs low CRP (&lt; 50 mg/dL)
Age &lt; 60 years vs age 60 - 70 years vs age &gt; 70 years
Anthonissen I vs Anthonissen II vs Anthonissen III at admission
ICS use vs no ICS use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days of intensive care</measure>
    <time_frame>Will be assessed on day 90 (last day of treatment phase) and day 270 (last day of follow-up phase)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Secondary outcome measure will also be analysed in following subgroups:
Male vs female
Smoker vs ex-smoker (stopped smoking &gt; 6 months)
GOLD A, B vs GOLD C vs GOLD D
former GOLD  I, II vs III vs IV
High CRP (&gt; 50 mg/dL) vs low CRP (&lt; 50 mg/dL)
Age &lt; 60 years vs age 60 - 70 years vs age &gt; 70 years
Anthonissen I vs Anthonissen II vs Anthonissen III at admission
ICS use vs no ICS use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom and quality of life scores</measure>
    <time_frame>Will be assessed on day 90 (last day of treatment phase) and day 270 (last day of follow-up phase)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Secondary outcome measure will also be analysed in following subgroups:
Male vs female
Smoker vs ex-smoker (stopped smoking &gt; 6 months)
GOLD A, B vs GOLD C vs GOLD D
former GOLD  I, II vs III vs IV
High CRP (&gt; 50 mg/dL) vs low CRP (&lt; 50 mg/dL)
Age &lt; 60 years vs age 60 - 70 years vs age &gt; 70 years
Anthonissen I vs Anthonissen II vs Anthonissen III at admission
ICS use vs no ICS use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre- and post-bronchodilator FEV1</measure>
    <time_frame>Will be assessed on day 90 (last day of treatment phase) and day 270 (last day of follow-up phase)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Secondary outcome measure will also be analysed in following subgroups:
Male vs female
Smoker vs ex-smoker (stopped smoking &gt; 6 months)
GOLD A, B vs GOLD C vs GOLD D
former GOLD  I, II vs III vs IV
High CRP (&gt; 50 mg/dL) vs low CRP (&lt; 50 mg/dL)
Age &lt; 60 years vs age 60 - 70 years vs age &gt; 70 years
Anthonissen I vs Anthonissen II vs Anthonissen III at admission
ICS use vs no ICS use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total dose of systemic steroids</measure>
    <time_frame>Will be assessed on day 90 (last day of treatment phase) and day 270 (last day of follow-up phase)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Secondary outcome measure will also be analysed in following subgroups:
Male vs female
Smoker vs ex-smoker (stopped smoking &gt; 6 months)
GOLD A, B vs GOLD C vs GOLD D
former GOLD  I, II vs III vs IV
High CRP (&gt; 50 mg/dL) vs low CRP (&lt; 50 mg/dL)
Age &lt; 60 years vs age 60 - 70 years vs age &gt; 70 years
Anthonissen I vs Anthonissen II vs Anthonissen III at admission
ICS use vs no ICS use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total days of antibiotic use</measure>
    <time_frame>Will be assessed on day 90 (last day of treatment phase) and day 270 (last day of follow-up phase)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Secondary outcome measure will also be analysed in following subgroups:
Male vs female
Smoker vs ex-smoker (stopped smoking &gt; 6 months)
GOLD A, B vs GOLD C vs GOLD D
former GOLD  I, II vs III vs IV
High CRP (&gt; 50 mg/dL) vs low CRP (&lt; 50 mg/dL)
Age &lt; 60 years vs age 60 - 70 years vs age &gt; 70 years
Anthonissen I vs Anthonissen II vs Anthonissen III at admission
ICS use vs no ICS use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of home physician contacts</measure>
    <time_frame>Will be assessed on day 90 (last day of treatment phase) and day 270 (last day of follow-up phase)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Secondary outcome measure will also be analysed in following subgroups:
Male vs female
Smoker vs ex-smoker (stopped smoking &gt; 6 months)
GOLD A, B vs GOLD C vs GOLD D
former GOLD  I, II vs III vs IV
High CRP (&gt; 50 mg/dL) vs low CRP (&lt; 50 mg/dL)
Age &lt; 60 years vs age 60 - 70 years vs age &gt; 70 years
Anthonissen I vs Anthonissen II vs Anthonissen III at admission
ICS use vs no ICS use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average cost of hospitalization</measure>
    <time_frame>Will be assessed on day 90 (last day of treatment phase) and day 270 (last day of follow-up phase)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Secondary outcome measure will also be analysed in following subgroups:
Male vs female
Smoker vs ex-smoker (stopped smoking &gt; 6 months)
GOLD A, B vs GOLD C vs GOLD D
former GOLD  I, II vs III vs IV
High CRP (&gt; 50 mg/dL) vs low CRP (&lt; 50 mg/dL)
Age &lt; 60 years vs age 60 - 70 years vs age &gt; 70 years
Anthonissen I vs Anthonissen II vs Anthonissen III at admission
ICS use vs no ICS use</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Azithromycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>N = 250 From day 1 up to and including day 3:   500 mg azithromycin PO once a day From day 4 up to and including day 90: 250 mg azithromycin PO once every 2 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>N = 250 From day 1 up to and including day 3:   500 mg placebo PO once a day From day 4 up to and including day 90: 250 mg placebo PO once every 2 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>From day 1 up to and including day 3: 500 mg azithromycin or placebo PO once a day From day 4 up to and including day 90: 250 mg azithromycin or placebo PO once every 2 days</description>
    <arm_group_label>Azithromycin</arm_group_label>
    <other_name>Azitromcyine CF</other_name>
    <other_name>ATC code: J01FA10</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Established diagnosis of COPD by medical doctor (based on clinical history OR
             pulmonary function test)

          -  Smoking history of at least 10 pack-years (10 pack-years are defined as 20 cigarettes
             a day for 10 years, or 10 cigarettes a day for 20 years, etc.)

          -  Current hospitalization for potential infectious AECOPD treated with standard therapy

          -  History of at least one exacerbation during the last year (prior to the current
             hospital admission) for which systemic steroids and/or antibiotics were taken

          -  ECG at admission

        Exclusion Criteria:

          -  Mechanical or non-invasive ventilation at moment of randomization (D1)

          -  Long QT interval on ECG (QTc &gt; 450msec for males or &gt; 470msec for females)

          -  History of life-threatening arrhythmias

          -  Myocardial infarction (NSTEMI or STEMI) less than 6 weeks before start of study drug

          -  Unstable angina pectoris or acute myocardial infarction (NSTEMI or STEMI) at
             admission

          -  Drugs with high risk for long QT interval and torsade de pointes (amiodarone,
             flecainide, procainamide, sotalol, droperidol, haldol, citalopram, other macrolides)

          -  Documented uncorrected severe hypokalemia (K+ &lt; 3.0 mmol/L) or hypomagnesemia (Mg2+ &lt;
             0.5 mmol/L)

          -  Chronic systemic steroids (&gt; 4 mg methylprednisolone /day for ≥ 2 months)

          -  Actual use of macrolides for at least 2 weeks

          -  Allergy to macrolides

          -  Active cancer treatment

          -  Life expectancy &lt; 3 months

          -  Pregnant or breast-feeding subjects. Woman of childbearing potential must have a
             pregnancy test performed and a negative result must be documented before start of
             treatment
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wim Janssens, MD. PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>KU Leuven - UZ Leuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kristina Vermeersch, Master</last_name>
    <phone>016342284</phone>
    <phone_ext>0032</phone_ext>
    <email>kristina.vermeersch@uzleuven.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kristien De Bent, Master</last_name>
    <phone>016341701</phone>
    <phone_ext>0032</phone_ext>
    <email>kristien.debent@uzleuven.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UZ Brussel</name>
      <address>
        <city>Brussel</city>
        <state>Brussel Hoofdstedelijk Gewest</state>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniel Schuermans</last_name>
      <phone>024776346</phone>
      <phone_ext>0032</phone_ext>
      <email>daniel.schuermans@uzbrussel.be</email>
    </contact>
    <investigator>
      <last_name>Walter Vincken, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Pieterzienkenhuis</name>
      <address>
        <city>Brussel</city>
        <state>Brussels Hoofdstedelijk Gewest</state>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Frédérique De Cock</last_name>
      <phone>025354107</phone>
      <phone_ext>0032</phone_ext>
      <email>frederique_DECOCK@stpierre-bru.be</email>
    </contact>
    <investigator>
      <last_name>Vincent Ninane, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ZNA Middelheim</name>
      <address>
        <city>Antwerpen</city>
        <state>Vlaanderen</state>
        <zip>2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peter Janssens</last_name>
      <phone>032803527</phone>
      <phone_ext>0032</phone_ext>
      <email>peter.janssens@zna.be</email>
    </contact>
    <investigator>
      <last_name>Hans Slabbynck, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Augustinus Ziekenhuis</name>
      <address>
        <city>Antwerpen</city>
        <state>Vlaanderen</state>
        <zip>2610</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pascale Ardies</last_name>
      <phone>034433557</phone>
      <phone_ext>0032</phone_ext>
      <email>pascale.ardies@gza.be</email>
    </contact>
    <investigator>
      <last_name>Alix Debrock, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Imelda Ziekenhuis</name>
      <address>
        <city>Bonheiden</city>
        <state>Vlaanderen</state>
        <zip>2820</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tine Lauwerier, MD</last_name>
      <email>tine.lauwerier@imelda.be</email>
    </contact>
    <investigator>
      <last_name>Tine Lauwerier, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Jan Brugge Ziekenhuis</name>
      <address>
        <city>Brugge</city>
        <state>Vlaanderen</state>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christel Haenebalcke, MD</last_name>
      <email>christel.haenebalcke@azsintjan.be</email>
    </contact>
    <investigator>
      <last_name>Christel Haenebalcke, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <state>Vlaanderen</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bénédicte Demeyere</last_name>
      <phone>093322819</phone>
      <phone_ext>0032</phone_ext>
      <email>benedicte.demeyere@uzgent.be</email>
    </contact>
    <contact_backup>
      <last_name>Anja Delporte</last_name>
      <phone>093320228</phone>
      <phone_ext>0032</phone_ext>
      <email>anja.delporte@uzgent.be</email>
    </contact_backup>
    <investigator>
      <last_name>Guy Brusselle, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maria Middelaresziekenhuis</name>
      <address>
        <city>Gent</city>
        <state>Vlaanderen</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>An Casneuf</last_name>
      <phone>093298176</phone>
      <phone_ext>0032</phone_ext>
      <email>an.casneuf@telenet.be</email>
    </contact>
    <investigator>
      <last_name>Jan Lamont, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jessa Ziekenhuis</name>
      <address>
        <city>Hasselt</city>
        <state>Vlaanderen</state>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joseph Aumann, MD</last_name>
      <email>joseph.aumann@jessazh.be</email>
    </contact>
    <investigator>
      <last_name>Joseph Aumann, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Groeninge Ziekenhuis</name>
      <address>
        <city>Kortrijk</city>
        <state>Vlaanderen</state>
        <zip>8500</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Katleen Barra</last_name>
      <phone>056/633357</phone>
      <phone_ext>0032</phone_ext>
      <email>katleen.barra@azgroeninge.be</email>
    </contact>
    <investigator>
      <last_name>Michiel Haerens, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <state>Vlaanderen</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kristina Vermeersch, Master</last_name>
      <phone>016342284</phone>
      <phone_ext>0032</phone_ext>
      <email>kristina.vermeersch@uzleuven.be</email>
    </contact>
    <contact_backup>
      <last_name>Kristien De Bent, Master</last_name>
      <phone>016341701</phone>
      <phone_ext>0032</phone_ext>
      <email>kristien.debent@uzleuven.be</email>
    </contact_backup>
    <investigator>
      <last_name>Wim Janssens, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Heilig Hart Ziekenhuis</name>
      <address>
        <city>Roeselare</city>
        <state>Vlaanderen</state>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Melissa Masschelin</last_name>
      <phone>051237207</phone>
      <phone_ext>0032</phone_ext>
      <email>melissa.masschelin@azdelta.be</email>
    </contact>
    <contact_backup>
      <last_name>Lieke Seynaeve</last_name>
      <phone>051237656</phone>
      <phone_ext>0032</phone_ext>
      <email>lieke.seynaeve@azdelta.be</email>
    </contact_backup>
    <investigator>
      <last_name>Ingel Demedts, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Andriesziekenhuis</name>
      <address>
        <city>Tielt</city>
        <state>Vlaanderen</state>
        <zip>8700</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Evelien Rysman</last_name>
      <phone>051425172</phone>
      <phone_ext>0032</phone_ext>
      <email>evelien.rysman@sintandriestielt.be</email>
    </contact>
    <investigator>
      <last_name>Geert Tits, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Charleroi</name>
      <address>
        <city>Charleroi</city>
        <state>Wallonië</state>
        <zip>6110</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pascale Oumaziz</last_name>
      <phone>071921211</phone>
      <phone_ext>0032</phone_ext>
      <email>pascale.oumaziz@chu-charleroi.be</email>
    </contact>
    <investigator>
      <last_name>Rudi Peché, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Grand Hôpital de Charleroi</name>
      <address>
        <city>Gilly</city>
        <state>Wallonië</state>
        <zip>6060</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philippe Duwez</last_name>
      <phone>071107299</phone>
      <phone_ext>0032</phone_ext>
      <email>philippe.duwez@ghdc.be</email>
    </contact>
    <investigator>
      <last_name>Antoine Fremault, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Liège</name>
      <address>
        <city>Luik</city>
        <state>Wallonië</state>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Els Rubens</last_name>
      <phone>043667482</phone>
      <phone_ext>0032</phone_ext>
      <email>els.rubens@chu.ulg.ac.be</email>
    </contact>
    <investigator>
      <last_name>Jean-Louis Corhay, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Mont-Godinne</name>
      <address>
        <city>Yvoir</city>
        <state>Wallonië</state>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric Marchand, MD</last_name>
      <email>eric.marchand@uclouvain.be</email>
    </contact>
    <investigator>
      <last_name>Eric Marchand, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 13, 2014</lastchanged_date>
  <firstreceived_date>May 8, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Katholieke Universiteit Leuven</investigator_affiliation>
    <investigator_full_name>Wim Janssens</investigator_full_name>
    <investigator_title>MD. PhD</investigator_title>
  </responsible_party>
  <keyword>AECOPD</keyword>
  <keyword>Chronic Obstructive Pulmonary Disease</keyword>
  <keyword>Acute exacerbation</keyword>
  <keyword>Hospitalization</keyword>
  <keyword>Azithromycin</keyword>
  <keyword>Macrolides</keyword>
  <keyword>Randomized Controlled Trial</keyword>
  <keyword>Placebo</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Azithromycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
